PREBEN

PREBEN is a combination chemotherapy salvage regimen developed for the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) of both B- and T-cell phenotypes. The regimen consists of four active components: pixantrone, etoposide, bendamustine, and, in CD20-positive tumors, rituximab. It was developed by researchers at the University of Aarhus and evaluated in the Nordic Phase 1/2 PREBEN trial (NCT02678299). Pixantrone, the key novel component, is an aza-anthracenedione that acts as a DNA intercalator and topoisomerase II inhibitor with reduced cardiotoxicity compared to traditional anthracyclines. Etoposide also inhibits topoisomerase II, bendamustine is a bifunctional alkylating agent, and rituximab is a monoclonal antibody targeting the CD20 antigen. The regimen has shown efficacy in heavily pre-treated patients with diffuse large B-cell lymphoma (DLBCL), transformed indolent lymphoma, and peripheral T-cell lymphoma (PTCL).

Other names

pixantrone + rituximab + etoposide + bendamustinepixantrone + etoposide + bendamustine